title: Daily subcutaneous administration of recombinant human erythropoietin (rhEPO) in peritoneal dialysis patients: a European dose-response study.
abstract: In a prospective randomized open multicenter study, 107 anemic (Hct < = 28%) peritoneal dialysis (PD) patients were treated with s.c. rhEPO daily. The mean observation period was 299 days (range 14-479 days). Patients were randomly assigned to 3 groups with different initial doses: 5 U/kg (G5), 10 U/kg (G10), 20 U/kg (G20). Initial doses were maintained for at least 8 weeks unless the target Hct (30-35%) was achieved earlier. The weekly increase of Hct was significantly (p < 0.05) dose-dependent: 0.19% in G5, 0.5% in G10 and 0.94% in G20. In case of insufficient response (< 0.5% per week), the dose was doubled every 4 weeks. Final doses on achieving the target Hct ranged from 5 to 40 U/kg (median 20 U/kg). The dose was then reduced to 50% and adjusted individually. The median maintenance dose was 9.9 U/kg/day. No tendency towards higher blood pressure or intensification of antihypertensive treatment was observed. When rhEPO is administered daily, 10 U/kg/day (70 U/kg weekly) is the recommended starting dose. The need for higher doses used in unsatisfactory response, should lead to further examination to rule out iron deficiency and other reasons for non-response. The median maintenance dose reported here is the lowest published in the literature for PD patients and seems to be linked to the daily injections.
authors.affiliation: Hôpital Louis-Pasteur, Service de Néphrologie-Hemodialyse, Colmar, France.
authors.forename: B
authors.initials: B
authors.lastname: Faller
authors.forename: A
authors.initials: A
authors.lastname: Slingeneyer
authors.forename: M
authors.initials: M
authors.lastname: Waller
authors.forename: C
authors.initials: C
authors.lastname: Michel
authors.forename: P
authors.initials: P
authors.lastname: Grützmacher
authors.forename: H P
authors.initials: HP
authors.lastname: Müller
authors.forename: P
authors.initials: P
authors.lastname: Barany
authors.forename: B
authors.initials: B
authors.lastname: Grabensee
authors.forename: B
authors.initials: B
authors.lastname: Issad
authors.forename: H
authors.initials: H
authors.lastname: Schmitt
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000008:administration & dosage* / Q000627:therapeutic use; D005060:Europe; D005260:Female; D006400:Hematocrit; D006801:Humans; D007279:Injections, Subcutaneous; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin